Medical News Today -- Giving pemetrexed maintenance therapy to patients with non-small-cell lung cancer (NSCLC) who have not had disease progression after initial platinum-based chemotherapy improves both overall and progression-free survival. The findings are discussed in an Article published Online First and in an upcoming edition of The Lancet, written by Dr Chandra Belani, Penn State Hershey Cancer Institute, Hershey, PA, USA, and colleagues.
